Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study (BMC Cancer. (2017) 17 (332) DOI: 10.1186/s12885-017-3286-5);Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Sekulic, Aleksandar ^a   Migden, Michael R ^b   Basset Seguin, Nicole ^c   Garbe, Claus ^d   Gesierich, Anja ^e   Lao, Christopher D ^f   Miller, Chris ^g   Mortier, Laurent ^h   Murrell, Dedee F ⁱ   Hamid, Omid ^j   Quevedo, Jorge F ^k   Hou, Jeannie ^l   McKenna, Edward ^l   Dimier, Natalie ^m   Williams, Sarah ^m   Schadendorf, Dirk ⁿ   Hauschild, Axel ^o  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY OF MICHIGAN   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j Angeles Clinic and Research Institute   (United States)

^k MAYO CLINIC   (United States)

^l GENENTECH INC   (United States)

^m ROCHE PRODUCTS LTD   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Basal cell carcinoma (BCC); Efficacy; Long term; Safety; Vismodegib

Indexed keywords

VISMODEGIB; ABC TRANSPORTER; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; AGEUSIA; ALOPECIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CELLULITIS; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HIP FRACTURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGEUSIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RHINOPHARYNGITIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR;

ANILIDES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, BASAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEDGEHOG PROTEINS; HUMANS; MALE; PROSPECTIVE STUDIES; PYRIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 85019350607     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-019-5568-6     Document Type: Erratum

References (26)

1. Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res. 2013;5:197-203.
2. Wu S, Han J, Li W-Q, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in US women and men. Am J Epidemiol. 2013;178:890-7.
3. Lucas R, McMichael T, Smith W, Armstrong B. World Health Organization: Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental Burden of Disease Series, No. 13. Geneva, Switzerland, World Health Organization, 2006. http://www.who.int/uv/health/solaruvradfull_180706.pdf.
4. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;24:218-23.
5. Varga E, Korom I, Raskó Z, et al. Neglected basal cell carcinomas in the 21st century. J Skin Cancer. 2011;2011:392151.
6. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J. 2006;12:7.
7. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24:715-9.
8. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma: report of five cases. Cancer. 1994;73:328-35.
9. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58:1798-803.
10. Xie J, Murone M, Luoh S-M, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90-2.
11. Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258.
12. Daya-Grosjean L, Couvé-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett. 2005;225:181-92.
13. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502-11.
14. US Food and Drug Administration Web site. Vismodegib. January 2012. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 9 Nov 2016.
15. European Medicines Agency. European Public Assessment Report: Erivdege. July 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002602/WC500146821.pdf. Accessed 9 Nov 2016.
16. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716-28.
17. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16.
19. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
20. Sekulic A, Migden MR, Lewis K, et al. on behalf of the ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72:1021-6.e8.
21. Dummer R, Basset-Seguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. J Clin Oncol. 2015;33(suppl):abstr 9024.
22. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774-83.
23. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10:1043-60.
24. Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012;366:2225-6.
25. Basset-Seguin N, Hauschild A, Grob J-J, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16:729-36.
26. Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21:1218-29.